Oncology Evidence Evolution
5 evidence evolution narratives tracing how landmark trials and guideline updates reshaped oncology practice.
CAR-T Cell Therapy
From concept to clinical reality
Concept (1989) → ALL remissions → ELIANA/ZUMA-1 → DLBCL → CLL/myeloma → real-world toxicity
Immune Checkpoint Inhibitors
Unleashing the immune system
Ipilimumab melanoma (2011) → nivolumab/pembrolizumab → PD-L1 → combination → adjuvant/neoadjuvant
Antibody-Drug Conjugates in Solid Tumors
Smart bombs hit their targets
Concept failures → T-DM1 (EMILIA) → T-DXd (DESTINY-Breast) → sacituzumab → tumor-agnostic
PARP Inhibitors in DNA Repair-Deficient Cancers
Exploiting the Achilles heel of BRCA tumors
Synthetic lethality concept → olaparib (Study 19/SOLO-1) → rucaparib/niraparib → HRD-positive expansion → maintenance
Precision Oncology and Biomarker-Driven Therapy
From histology to molecular profiling
Histology-based → EGFR/ALK lung (IPASS) → NGS panels → tumor-agnostic approvals (KEYNOTE-158/larotrectinib) → ctDNA-guided